ArticleOncotarget2017
Low plasma levels of miR-101 are associated with tumor progression in gastric cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.British journal of cancer · 2024Pooled it
- Review
- Functions and Clinical Applications of Exosomes in Gastric Cancer.International journal of biological sciences · 2025Review
- Roles and application of exosomes in the development, diagnosis and treatment of gastric cancer.World journal of gastrointestinal oncology · 2024Review
- The Expression Patterns and Implications ofInternational journal of molecular sciences · 2023Article
- Plasma miR-1254 as a predictive biomarker of chemosensitivity and a target of nucleic acid therapy in esophageal cancer.Cancer science · 2023Article
- Profiling of microRNAs in actinic keratosis and cutaneous squamous cell carcinoma patients.Archives of dermatological research · 2022Article
- Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer.Cancers · 2022Review
- Association between the Expression Levels of MicroRNA-101, -103, and -29a with Autotaxin and Lysophosphatidic Acid Receptor 2 Expression in Gastric Cancer Patients.Journal of oncology · 2022Article
- Hypoxic stress suppresses lung tumor-secreted exosomal miR101 to activate macrophages and induce inflammation.Cell death & disease · 2021Article
- Circulating MicroRNAs in Gastrointestinal Cancer.Cancers · 2021Review
- MicroRNAs are involved in the development and progression of gastric cancer.Acta pharmacologica Sinica · 2021Review
- The Significance of Exosomal RNAs in the Development, Diagnosis, and Treatment of Gastric Cancer.Genes · 2021Review
- Depletion of tumor suppressor miRNA-148a in plasma relates to tumor progression and poor outcomes in gastric cancer.American journal of cancer research · 2021Article
- Competing Endogenous RNA Networks in the Epithelial to Mesenchymal Transition in Diffuse-Type of Gastric Cancer.Cancers · 2020Review
- Advances in the role of exosomal non-coding RNA in the development, diagnosis, and treatment of gastric cancer (Review).Molecular and clinical oncology · 2020Review
- Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer.Scientific reports · 2020Article
- Serum miR-101-3p combined with pepsinogen contributes to the early diagnosis of gastric cancer.BMC medical genetics · 2020Article
- CircAPLP2 regulates the proliferation and metastasis of colorectal cancer by targeting miR-101-3p to activate the Notch signalling pathway.American journal of translational research · 2020Article
- E-cadherin Downregulation and microRNAs in Sporadic Intestinal-Type Gastric Cancer.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral studies have identified the decreased expression of the tumor suppressor miR-101 in various cancers. In this study, we tested miR-101 as a potential therapeutic target and novel plasma biomarker for gastric cancer (GC).
resultsThe miR-101 expression level was significantly lower in GC tissues (
conclusionsDepletion of the tumor suppressor miRNA-101 in plasma is related to tumor progression and poor outcomes. Low plasma miR-101 may be a biomarker for GC, and its restoration might be a novel anticancer treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.